3rd Annual Immuno-Oncology: BD&L and Investment Forum 2017 | Sachs Associates Ltd | 2 June 2017 | Chicago, Illinois, United States

Taking place on the first day of ASCO, the 3rd Annual Immuno-Oncology: BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment. Numerous networking opportunities available via an online one-to-one meeting system with dedicated meeting facilities to make the event more transactional.

Keynote:
Samuele Butera
Global Cell & Gene Therapies Business Leader
Novartis Oncology

Aaron Foster
Vice President of Product Discovery
Bellicum Pharmaceuticals, Inc.

Axel Hoos
SVP, TA Head
Oncology R&D, GSK

Bard Geesaman
Managing Director
MPM Capital

Bibhash Mukhopadhyay
Principal
New Enterprise Associates

Biren Amin
Managing Director
Jefferies LLC

Boris Peaker
Managing Director
Biotechnology Equity research
Cowen Group*

Brad Loncar
Portfolio Manager
Loncar Investment, LLC

Chris DeRespino
Business Development
Amgen Inc.

Claus Deichgræber
VP Business Development
Oncology Venture

David Malek
Chief Business Officer
BioLineRx Ltd.

Debra Bowes, EVP
Business and Strategic Development
MaxCyte, Inc.

Ferran Prat, VP
Strategic Industry Ventures
MD Anderson Cancer Center

Gary Sclar
Vice President
Dana-Farber Innovations
Dana-Farber Cancer Institute

Greg Naeve
Head of Strategic Research Partnerships
Oncology, Pfizer, Inc.

Gregory Frost
CEO and Chairman, F1BioVentures

Guillaume Vignon
Head of Immuno-Oncology Licensing & Business Development
Merck

Helen Chen
Managing Director and Head of China Life Sciences
L.E.K. Consulting

Helen Tayton-Martin
Chief Business Officer
Adaptimmune Therapeutics

Hongbo Lu
Partner
Lilly Asian Venture

Howard Fingert
Senior Medical Director for Clinical Intelligence
Takeda Pharmaceuticals

Ian Woo
Managing Director
Healthcare Banking
Lazard

James Mulé
Associate Center Director for Translational Research
Moffitt Cancer Center

Ji Li
Global Head of Business Development
BeiGene

John Beadle
CEO, PsiOxus Therapeutics Ltd.

Joseph Sum
Director of Research
EcoR1 Capital, LLC

Juergen Gamer
VP Business Development
Apogenix AG

Julie Locklear
Vice President & Head Health Economics & Outcomes Research
EMD Serono, Inc.

Kuldeep Neote
Senior Director
New Ventures

Lee Greenberger
SVP and CSO
The Leukemia & Lymphoma Society

Lindy Durrant
CSO,Scancell Limited

Lisa Decker
Executive Director
Business Development
Nektar Therapeutics

Loic Vincent
Head
Immunology Partnerships
Takeda Pharmaceuticals

Michael Margolis
Co-Head of Healthcare Investment Banking
Oppenheimer & Co. Inc.

Mike Rice
Principal
Defined Health
a Cello Health Business

Patrick Tricoli
CEO, Nanobiotix Corp.

Paul Rennert
President & CSO
Aleta Biotherapeutics

Peter Emtage
Senior Vice President Research and Translational Medicine
Cell Design Labs

Peter Sandor
VP, Oncology Therapeutic Area Head for Marketing Strategy
Astellas

Peter Thompson
Private Equity Partner
OrbiMed Advisors LLC

Rahul Jasuja
CEO & Board Member
Pelican Therapeutics

Rena Conti
Assistant Professor Hematology/Oncology
Department of Pediatrics
The University of Chicago

Sachin Kamal-Bahl
Vice President and Head
Innovation Center
Patient & Health Impact
Pfizer, Inc.

Samuele Butera
Global Cell & Gene Therapies Business Leader
Novartis Oncology

Stefan Glück
VP GMA Early Assets
Celgene

Stephen Sands
BD&L Director Oncology/Immunology
F. Hoffmann La Roche Ltd.

Thilo Schroeder
Partner
Nextech Invest Ltd.

Timothy Herpin
VP, Head of Transactions (UK)
Business Development
AstraZeneca

Walter Lau
Managing Partner
Cenova Venture

Yuwen Liu
Founding Partner
BoHe Angel Fund

And more TBA...

No indicated event sponsors in their website.